BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• 

  Government

  Makary Considers More Cuts at FDA Amid Continued Delays

  According to an internal email, the agency may be in for more consolidation in areas including human resources, communications, travel and acquisitions.

  June 16, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

  Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supernus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January.

  June 16, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Weight loss

  Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo

  At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.

  June 16, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Collaboration

  Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off

  At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile’ period for the industry.

  June 16, 2025

   · 

  2 min read

   · 

  Jef Akst
• 

  Antibody-drug conjugate (ADC)

  NextCure Joins China-ADC Gold Rush with $745M Simcere Deal

  The deal gets NextCure the rights to Simcere’s novel ADC for solid tumors outside of China.

  June 16, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Duchenne muscular dystrophy

  UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys

  Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from acute liver failure, a known side effect of adeno-associated virus-based gene therapies.

  June 16, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Regeneron Backs Off 23andMe, Losing Bid to Former CEO

  Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.

  June 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cell therapy

  J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study

  Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gilead’s Yescarta.

  June 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Parkinson’s disease

  Roche, Prothena Push Parkinson’s Drug to Phase III Despite Mid-Stage Fail

  Analysts at Jefferies give Roche and Prothena’s Phase III study just a 25% to 40% probability of success.

  June 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe

  While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play its cards right to attract more studies.

  June 16, 2025

   · 

  6 min read

   · 

  Craig Koch